Boyer DE, Cortés RP, Rodríguez GA, Espinosa LF

Language: Spanish
References: 11
Page: 40-44
PDF size: 175.38 Kb.

ABSTRACT

Introduction: Primary hyperparathyroidism (PPH) is the third most frequent endocrine disorder in the world with an estimated prevalence of 1% in people over 65 years. It is characterized by the presence of elevated calcium levels and elevated levels of paratohormone (PTH). The objective of this retrospective study is to describe clinical and demographic characteristics of patients with PPH, who had parathyroidectomy in a third level private hospital in Mexico City. Material and methods: Retrospective study of a group of patients diagnosed with PPH who had parathyroidectomy, by different surgeons, period from January 2015 to December 2018. We included 31 patients of which the data was obtained from pathology service; clinical, demographic, laboratory and surgery data were recorded. Results: The average age of the study population was 56.48 years (SD ± 13.7), 24 (77.41%) were women. Main cause was adenoma. In the multivariate logistic regression analysis, the independent risk factors for the duration of surgery greater than 60 minutes were hypertension and dyslipidemia, all patients achieved normocalcemia, without there being any trans-surgical or post-surgical complications. Conclusions: Hypertension and dyslipidemia are identified as independent risk factors for longer duration (> 60 minutes) for parathyroidectomy. Parathyroidectomy is a curative procedure in expert hands.

REFERENCES

1. Yu N, Donnan PT, Murphy MJ, Leese GP. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol (Oxf). 2009; 71 (4): 485-493.

2. Fraser WD. Hyperparathyroidism. Lancet. 2009; 374 (9684): 145-158.

3. Gasser RW. Clinical aspects of primary hyperparathyroidism: clinical manifestations, diagnosis, and therapy. Wien Med Wochenschr. 2013; 163 (17-18): 397-402.

4. Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018; 391 (10116): 168-178. doi: 10.1016/S0140-6736(17)31430-7.

5. Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017; 28 (1): 1-19.

6. Khan AA. Medical management of primary hyperparathyroidism. J Clin Densitom. 2013; 16 (1): 60-63.

7. Pallan S, Rahman MO, Khan AA. Diagnosis and management of primary hyperparathyroidism. BMJ. 2012; 344: e1013. doi: 10.1136/bmj.e1013.

8. Granados Canseco E, Servín Torres E, Piscil Salazar MA, Velázquez García JA, Serrano Galeana I, Granados Canseco R et al. Experiencia quirúrgica en el hiperparatiroidismo primario en el Hospital de Especialidades del Centro Médico Nacional "La Raza". Cir Gen. 2012; 34 (4): 249-253.

9. Udelsman R, Akerstrom G, Biagini C, Duh QY, Miccoli P, Niederle B et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014; 99 (10): 3595-3606.

10. Komaba H, Kakuta T, Fukagawa M. Management of secondary hyperparathyroidism: how and why? Clin Exp Nephrol. 2017; 21 (Suppl 1): 37-45.

11. Concistre A, Grillo A, La Torre G, Carretta R, Fabris B, Petramala L etal. Ambulatory blood pressure monitoring-derived short-term blood pressure variability in primary hyperparathyroidism. Endocrine. 2018; 60 (1): 129-137.